Metal-Induced Diffuse Lung Disease

Andrew P. Fontenot; Massimo Amicosante

doi:10.1055/s-0028-1101276

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2008; 29(6): 662-669
DOI: 10.1055/s-0028-1101276

Metal-Induced Diffuse Lung Disease

Andrew P. Fontenot¹ ^, ² , Massimo Amicosante³

¹Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado
²Department of Immunology, University of Colorado Health Sciences Center, Denver, Colorado
³Department of Internal Medicine, University of Rome “Tor Vergata,” Rome, Italy

Abstract

ABSTRACT

The number of metals that are associated with the development of diffuse parenchymal lung disease continues to expand. In addition to lung fibrosis, inhalation of metal particulates can induce a wide range of lung pathology, including reactive airways disease and cancer. This article focuses on diffuse parenchymal diseases resulting from the inhalation of beryllium and cobalt. More is known regarding the immunopathogenesis of beryllium-induced disease than is known for disease induced by any other metal. Chronic beryllium disease (CBD) is a granulomatous lung disorder caused by beryllium exposure in the workplace and is characterized by the accumulation of beryllium-specific CD4⁺ T cells in the bronchoalveolar lavage. Genetic susceptibility markers associated with increased risk have been identified for both CBD and hard metal lung disease. The mechanism for the genetic susceptibility of CBD lies in the ability of certain human leukocyte antigen (HLA)-DP molecules to bind and present beryllium to pathogenic CD4⁺ T cells. Whether the same is true for hard metal lung disease is unknown. In contrast, no HLA allelic association has been identified in nickel allergic subjects. The study of metal-induced lung disease allows the investigation of the relationship between environmental exposure and genetic susceptibility. These studies will enhance our understanding of the immunopathogenesis of metal-induced disease and how exposure to these metals results in irreversible lung fibrosis.

KEYWORDS

Lung - metals - T cells - genetic susceptibility - fibrosis - granuloma

Volltext

Referenzen

REFERENCES

1 Newman L S, Maier L A. Beryllium disease. In: Schwarz MI, King TE Jr Interstitial Lung Disease. 3rd ed. Hamilton; BC Decker 2003: 435-451
2 Kelleher P C, Martyny J W, Mroz M M et al.. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med. 2001; 43 238-249
3 Kreiss K, Mroz M M, Newman L S, Martyny J, Zhen B. Machining risk of beryllium disease and sensitization with median exposures below 2 μg/m³ . Am J Ind Med. 1996; 30 16-25
4 Kreiss K, Newman L S, Mroz M, Campbell P A. Screening blood test identifies subclinical beryllium disease. J Occup Med. 1989; 31 603-608
5 Kreiss K, Wasserman S, Mroz M M, Newman L S. Beryllium disease screening in the ceramics industry: blood test performance and exposure-disease relations. J Occup Med. 1993; 35 267-274
6 Kreiss K, Mroz M M, Zhen B, Martyny J W, Newman L S. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993; 148 985-991
7 Henneberger P K, Cumro D, Deubner D D, Kent M S, McCawley M, Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health. 2001; 74 167-176
8 Newman L S, Mroz M M, Balkissoon R, Maier L A. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med. 2004; 171 54-60
9 Fontenot A P, Newman L S, Kotzin B L. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol. 2001; 100 4-14
10 Fontenot A P, Kotzin B L. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity. Tissue Antigens. 2003; 62 449-458
11 Newman L S, Kreiss K, King Jr T E, Seay S, Campbell P A. Pathologic and immunologic alterations in early stages of beryllium disease: re-examination of disease definition and natural history. Am Rev Respir Dis. 1989; 139 1479-1486
12 Williams W J, Kelland D. New aid for diagnosing chronic beryllium disease (CBD): laser ion mass analysis (LIMA). J Clin Pathol. 1986; 39 900-901
13 Williams W J, Wallach E R. Laser microprobe mass spectrometry (LAMMS) analysis of beryllium, sarcoidosis, and other granulomatous diseases. Sarcoidosis. 1989; 6 111-117
14 Newman L S, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect. 1996; 104 (Suppl 5) 937-943
15 Rossman M D, Kern J A, Elias J A et al.. Proliferative response of bronchoalveolar lymphocytes to beryllium. Ann Intern Med. 1988; 108 687-693
16 Saltini C, Winestock K, Kirby M, Pinkston P, Crystal R G. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989; 320 1103-1109
17 Saltini C, Kirby M, Trapnell B C, Tamura N, Crystal R G. Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med. 1990; 171 1123-1140
18 Fontenot A P, Falta M T, Freed B M, Newman L S, Kotzin B L. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol. 1999; 163 1019-1026
19 Fontenot A P, Kotzin B L, Comment C E, Newman L S. Expansions of T-cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease. Am J Respir Cell Mol Biol. 1998; 18 581-589
20 Fontenot A P, Maier L A, Canavera S J et al.. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol. 2002; 168 3627-3634
21 Fontenot A P, Canavera S J, Gharavi L, Newman L S, Kotzin B L. Target organ localization of memory CD4⁺ T cells in patients with chronic beryllium disease. J Clin Invest. 2002; 110 1473-1482
22 Pott G B, Palmer B E, Sullivan A K et al.. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4⁺ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol. 2005; 115 1036-1042
23 Fontenot A P, Palmer B E, Sullivan A K et al.. Frequency of beryllium-specific, central memory CD4⁺ T cells in blood determines proliferative response. J Clin Invest. 2005; 115 2886-2893
24 Tinkle S S, Kittle L A, Schumacher B A, Newman L S. Beryllium induces IL-2 and IFN-γ in berylliosis. J Immunol. 1997; 158 518-526
25 Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993; 262 242-244
26 Richeldi L, Kreiss K, Mroz M M, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997; 32 337-340
27 Wang Z, White P S, Petrovic M et al.. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999; 163 1647-1653
28 Saltini C, Richeldi L, Losi M et al.. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001; 18 677-684
29 Wang Z, Farris G M, Newman L S et al.. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology. 2001; 165 27-38
30 Rossman M D, Stubbs J, Lee C W, Argyris E, Magira E, Monos D. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med. 2002; 165 788-794
31 Maier L A, McGrath D S, Sato H et al.. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003; 171 6910-6918
32 McCanlies E C, Ensey J S, Schuler C R, Kreiss K, Weston A. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med. 2004; 46 95-103
33 Amicosante M, Berretta F, Rossman M et al.. Identification of HLA-DRPheß47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res. 2005; 6 94
34 Fontenot A P, Torres M, Marshall W H, Newman L S, Kotzin B L. Beryllium presentation to CD4⁺ T cells underlies disease susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci U S A. 2000; 97 12717-12722
35 Lombardi G, Germain C, Uren J et al.. HLA-DP allele-specific T cell responses to beryllium account for DP- associated susceptibility to chronic beryllium disease. J Immunol. 2001; 166 3549-3555
36 Bill J R, Mack D G, Falta M T et al.. Beryllium presentation to CD4 + T cells is dependent on a single amino acid residue of the MHC class II beta-chain. J Immunol. 2005; 175 7029-7037
37 Fontenot A P, Keizer T S, McCleskey M et al.. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4 + T cells. J Immunol. 2006; 177 3874-3883
38 De Wall S L, Painter C, Stone J D et al.. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol. 2006; 2 197-201
39 Penzotti J E, Nepom G T, Lybrand T P. Use of T cell receptor/HLA-DRB1*04 molecular modeling to predict site- specific interactions for the DR shared epitope associated with rheumatoid arthritis. Arthritis Rheum. 1997; 40 1316-1326
40 Amicosante M, Fontenot A P. T cell recognition in chronic beryllium disease. Clin Immunol. 2006; 121 134-143
41 Kelleher P, Pacheco K, Newman L S. Inorganic dust pneumonias: the metal-related parenchymal disorders. Environ Health Perspect. 2000; 108(Suppl 4) 685S-696S
42 Cowie R, Murray J, Becklake M. Pneumoconioses. In: Mason R, Murray J, Broaddus V, Nadel J Murray and Nadel's Textbook of Respiratory Medicine. 4th ed. Philadelphia; Elsevier/Saunders 2005: 1748-1782
43 Meyer-Bisch C, Pham Q T, Mur J M et al.. Respiratory hazards in hard metal workers: a cross sectional study. Br J Ind Med. 1989; 46 302-309
44 Sprince N L, Chamberlin R I, Hales C A, Weber A L, Kazemi H. Respiratory disease in tungsten carbide production workers. Chest. 1984; 86 549-557
45 Sprince N L, Oliver L C, Eisen E A, Greene R E, Chamberlin R I. Cobalt exposure and lung disease in tungsten carbide production. A cross-sectional study of current workers. Am Rev Respir Dis. 1988; 138 1220-1226
46 Zou S, Zou T, Ma F. An epidemiologic study on pulmonary fibrosis caused by hard alloy dust. Zhonghua Yu Fang Yi Xue Za Zhi. 1995; 29 70-72
47 Posgay M, Nemeth L, Mester A. Radiological aspects of hard metal disease. Rofo. 1993; 159 439-443
48 Frost A E, Keller C A, Brown R W et al.. Giant cell interstitial pneumonitis: disease recurrence in the transplanted lung. Am Rev Respir Dis. 1993; 148 1401-1404
49 Forni A. Bronchoalveolar lavage in the diagnosis of hard metal disease. Sci Total Environ. 1994; 150 69-76
50 Al-Tawil N G, Marcusson J A, Moller E. In vitro testing for cobalt sensitivity: an aid to diagnosis. Acta Derm Venereol. 1984; 64 203-208
51 Kusaka Y, Nakano Y, Shirakawa T, Morimoto K. Lymphocyte transformation with cobalt in hard metal asthma. Ind Health. 1989; 27 155-163
52 Potolicchio I, Mosconi G, Forni A, Nemery B, Seghizzi P, Sorrentino R. Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol. 1997; 27 2741-2743
53 Potolicchio I, Festucci A, Hausler P, Sorrentino R. HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease. Eur J Immunol. 1999; 29 2140-2147
54 Voisin C, Fisekci F, Buclez B et al.. Mineralogical analysis of the respiratory tract in aluminum oxide–exposed workers. Eur Respir J. 1996; 9 1874-1879
55 Lindenschmidt R C, Driscoll K E, Perkins M A, Higgins J M, Maurer J K, Belfiore K A. The comparison of a fibrogenic and two nonfibrogenic dusts by bronchoalveolar lavage. Toxicol Appl Pharmacol. 1990; 102 268-281
56 Armstrong C W, Moore Jr L W, Hackler R L, Miller Jr G B, Stroube R B. An outbreak of metal fume fever: diagnostic use of urinary copper and zinc determinations. J Occup Med. 1983; 25 886-888
57 Cohen S R. A review of the health hazards from copper exposure. J Occup Med. 1974; 16 621-624
58 Ostiguy G, Vaillancourt C, Begin R. Respiratory health of workers exposed to metal dusts and foundry fumes in a copper refinery. Occup Environ Med. 1995; 52 204-210
59 Pimentel J C, Marques F. “Vineyard sprayer's lung”: a new occupational disease. Thorax. 1969; 24 678-688
60 Villar T G. Vineyard sprayer's lung: clinical aspects. Am Rev Respir Dis. 1974; 110 545-555
61 Townshend R H. Acute cadmium pneumonitis: a 17-year follow-up. Br J Ind Med. 1982; 39 411-412
62 Budinger L, Hertl M. Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview. Allergy. 2000; 55 108-115
63 Moulon C, Vollmer J, Weltzien H U. Characterization of processing requirements and metal cross-reactivities in T cell clones from patients with allergic contact dermatitis to nickel. Eur J Immunol. 1995; 25 3308-3315
64 Emtestam L, Zetterquist H, Olerup O. HLA-DR, -DQ and -DP alleles in nickel, chromium, and/or cobalt-sensitive individuals: genomic analysis based on restriction fragment length polymorphisms. J Invest Dermatol. 1993; 100 271-274
65 Sinigaglia F, Scheidegger D, Garotta G, Scheffer R, Pletscher M, Lanzavecchia A. Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol. 1985; 135 3929-3932
66 Vollmer J, Weltzien H U, Dormoy A, Pistoor F, Moulon C. Functional expression and analysis of a human HLA-DQ restricted, nickel-reactive T cell receptor in mouse hybridoma cells. J Invest Dermatol. 1999; 113 175-181
67 Sinigaglia F. The molecular basis of metal recognition by T cells. J Invest Dermatol. 1994; 102 398-401
68 Romagnoli P, Labhardt A M, Sinigaglia F. Selective interaction of Ni with an MHC-bound peptide. EMBO J. 1991; 10 1303-1306
69 Lu L, Vollmer J, Moulon C, Weltzien H U, Marrack P, Kappler J. Components of the ligand for a Ni + + reactive human T cell clone. J Exp Med. 2003; 197 567-574

Andrew P FontenotM.D.

Division of Clinical Immunology (B-164), University of Colorado Health Sciences Center

4200 East Ninth Ave., Denver, CO 80262

eMail: andrew.fontenot@uchsc.edu